Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 August 2021 | Story Leonie Bolleurs | Photo Supplied
Prof Carlien Pohl-Albertyn, a successful scientist, is living her dream job, as she gets to pursue her passion for microbiology; a career she wanted to pursue ever since Grade 10.

Prof Carlien Pohl-Albertyn, a professor of Microbiology in the Department of Microbiology and Biochemistry, is the holder of the SARChI Chair in Pathogenic Yeasts at the University of the Free State (UFS). She is leading the Pathogenic Yeast Research Group, studying pathogenic yeast infections and necessary treatment options and bringing hope to many immunosuppressed patients battling HIV/Aids, cancer, diabetics, and other diseases. She also recently co-authored an article on the incidence of fungal infections in COVID-19 patients. 

“This is my dream job, as I get to pursue my passion for microbiology,” says Prof Pohl-Albertyn, who already knew as early as Grade 10 that she wanted to become a microbiologist. “I have always been fascinated by the natural world and have known since childhood that I would become a scientist,” she says. 

An interview with Prof Pohl-Albertyn reveals more about the persons who inspired her, her view on the development of women, and how she approaches her work. 

Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?

“The first woman who instilled a love for the biological sciences in me was Miss Steyn, my high school Biology teacher. She had a passion for teaching that inspired me to become a microbiologist.”

Prof Pohl-Albertyn, however, states that there were many other women who constantly inspired her to be a better person. 

“My mother inspires me to take responsibility for my choices; my mother-in-law inspires me to be kinder to others; and my best friends’ mothers inspire me to persevere, even when things are difficult.”

“I am also inspired by my female friends, Ezelle van den Heever, who has shown me that there is always a plan to be made to solve a problem; Trudi O’Neill, who manages to balance high-level research, teaching, and administration with her home life; Alicia Sherriff, from whom I am learning to be more emotionally intelligent; and Janine Allen, who has expanded my horizons and regularly shows me how to look at the world in a completely different way.”

What is your response to current challenges faced by women and available platforms for women development?

“Coming from a fairly male-dominated cultural background, I realise that I have been very privileged to not experience challenges just because I am a woman. I have been able to study and work in a field that values women and men equally and have chosen a very capable and extremely supportive husband, who sees me as an equal.”

She, however, realises that this is not the case for many women, and understands that there are women who were not able to follow their dreams and make their own life choices.

Prof Pohl-Albertyn believes that any opportunity for women to overcome challenges should be encouraged, as a society will ultimately be better if everyone is able to fulfil their greatest potential.

What advice would you give to the 15-year-old you?

This successful scientist, spouse, mother of two sons, daughter, friend, and mentor to many, says that she will advise her 15-year-old self to do everything the way that she has been doing it. “I do not regret anything and would not change my life in any way,” she says. 

What would you say makes you a woman of quality, impact, and care?

“I am a person of quality because of my integrity, work ethic, and commitment to my responsibilities – something that is easy if you enjoy what you do every day.”

“I am a person of impact because of the influence I have on my colleagues, who I always treat with respect, and my students, who I teach to the best of my abilities, and which I hope will serve them well in their careers.”

“I am a person of care because I value the contributions of my colleagues and students to my own growth and development,” remarks Prof Pohl-Albertyn.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept